|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Vaccines: Strong Innovation But Far Away From Capitalization
Datamonitor, Dec 2003, Pages: 148
Introduction
The therapeutic vaccine market is in its infancy with no significant products launched across the seven major markets. Despite the unproven nature of the sector in terms of market potential, it is commanding considerable interest across the biotechnology industry. Indeed. Datamonitor has identified 65 companies developing therapeutic vaccines, with 167 products in development.
Scope
Benchmarking of the current and future vaccine market, by technology and therapeutic focus, in terms of number of projects and dollar value
Assesses the steps that emerging players are taking to increase innovation in their businesses, integrate supply chain and improve strategic position
Analysis of market trends and future opportunities for both biotech and pharmaceutical players, with supporting case studies
Full profiles of 6 leading therapeutic vaccine players, encompassing company strategy, alliance networking, portfolio and pipeline analysis
Report Highlights
The therapeutic vaccine market will not receive significant attention from the wider pharmaceutical industry until a product is launched and achieves significant uptake across the seven major markets. The most likely drug to achieve this is Dendreon’s Provenge, although Dendreon must recruit a marketing partner before this can be achieved.
For companies that are totally focused on therapeutic vaccines, the only way to survive is through a strong network of partners. The unproven technology behind therapeutic vaccines, combined with the number of setbacks that the leading products have encountered, is inhibiting therapeutic vaccine companies’ abilities to form partnerships.
Oncology dominates therapeutic vaccines both in terms of commercial potential and pipeline development. Colorectal, melanoma and prostate cancer have the most therapeutic vaccines in development. However, the therapeutic vaccine early stage pipeline is split across more therapy areas, with an increased focus on infectious disease, CNS and HIV.
Reasons to Purchase
Benchmark your position within the vaccine market and identify the optimum strategy for future success
Forecast how advances in science and changes in the commercial environment will offer new opportunities to benefit from therapeutic vaccines
Identify key pipeline products for in-licensing opportunities as well as areas of unmet need
Customers who bought this item also bought
Br. Holdings Corporation
Br Malls Participacoes Sa
Therapeutic Cancer Vaccines: Evolving Strategies and Pipeline Prospects
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Chinese Markets for Polybutadiene Rubber (BR)
Strategic Perspectives 2001: Vaccines
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
The 2009 Import and Export Market for Butadiene Rubber (BR) in Estonia
|
|
|
|
